ATE450622T1 - Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit - Google Patents

Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit

Info

Publication number
ATE450622T1
ATE450622T1 AT02777275T AT02777275T ATE450622T1 AT E450622 T1 ATE450622 T1 AT E450622T1 AT 02777275 T AT02777275 T AT 02777275T AT 02777275 T AT02777275 T AT 02777275T AT E450622 T1 ATE450622 T1 AT E450622T1
Authority
AT
Austria
Prior art keywords
genes
cardiovascular disease
prognosis
prediction
prevention
Prior art date
Application number
AT02777275T
Other languages
English (en)
Inventor
Marc Munnes
Mathias Gehrmann
Maresa Wick
Gerd Schmitz
Original Assignee
Siemens Healthcare Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics filed Critical Siemens Healthcare Diagnostics
Application granted granted Critical
Publication of ATE450622T1 publication Critical patent/ATE450622T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT02777275T 2001-10-08 2002-10-02 Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit ATE450622T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124145.4A GB0124145D0 (en) 2001-10-08 2001-10-08 Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
PCT/EP2002/011034 WO2003031650A2 (en) 2001-10-08 2002-10-02 Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease

Publications (1)

Publication Number Publication Date
ATE450622T1 true ATE450622T1 (de) 2009-12-15

Family

ID=9923436

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02777275T ATE450622T1 (de) 2001-10-08 2002-10-02 Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit

Country Status (6)

Country Link
EP (1) EP1436425B1 (de)
AT (1) ATE450622T1 (de)
AU (1) AU2002338852A1 (de)
DE (1) DE60234619D1 (de)
GB (1) GB0124145D0 (de)
WO (1) WO2003031650A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002332929A1 (en) 2001-09-07 2003-03-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy39
AU2004268180A1 (en) * 2003-08-29 2005-03-10 Integragen Human obesity susceptibility gene and uses thereof
EP1522857A1 (de) 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
WO2005095641A1 (en) * 2004-03-03 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 11 (map3k11)
WO2006041835A2 (en) 2004-10-04 2006-04-20 University Of Washington Methods of inhibiting cell death or inflammation in a mammal
US20110021433A1 (en) * 2004-10-04 2011-01-27 Harlan John M Methods for treating or preventing heart failure
US8648045B2 (en) 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
EP2371846B1 (de) * 2005-03-10 2013-12-04 Ben Gurion University of the Negev Research and Development Authority Ltd. Zusammensetzungen des spannungsabhängigen anionenkanals (vdac1) und verfahren zu deren anwendung bei der regulierung der apoptose
EP1934348B1 (de) 2005-10-11 2018-05-02 Ben-Gurion University Of The Negev Research And Development Authority Zusammensetzung zum silencing der expression von vdac1 und verwendungen davon
US8815519B2 (en) 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
US7550300B1 (en) 2007-11-29 2009-06-23 Capgen Sciences, Inc. Prediction of bare metal stent restenosis
WO2009092382A1 (en) * 2008-01-23 2009-07-30 Rigshospitalet, Region Hovedstaden Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
WO2010037181A1 (en) * 2008-10-03 2010-04-08 The Walter And Eliza Hall Institute Of Medical Research Cell therapy and compositions therefor
CN102576028A (zh) 2009-08-25 2012-07-11 保函医药公司 半乳凝集素-3和心脏再同步疗法
WO2015011711A1 (en) 2013-07-25 2015-01-29 The National Institute for Biotechnology in the Negev Ltd. Short peptides derived from vdac1, compositions and methods of use thereof
AU2016304794B2 (en) 2015-08-07 2021-07-15 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
US11174484B2 (en) 2015-11-10 2021-11-16 B. G. Negev Technologies And Applications Ltd., At Ben- Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
BR112020001653A2 (pt) 2017-07-26 2020-07-21 Forty Seven, Inc. anticorpos anti-sirp-alfa e métodos relacionados
CN114126648A (zh) 2019-05-31 2022-03-01 Alx肿瘤生物技术公司 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法
CN121243368A (zh) 2019-11-27 2026-01-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
WO2024137306A1 (en) * 2022-12-22 2024-06-27 University Of Utah Research Foundation Compositions and methods for treating diabetic cardiomyopathy
WO2025240625A1 (en) * 2024-05-15 2025-11-20 University Of Utah Research Foundation Cbin1 therapy improves atrial electrical and functional remodeling, limiting atrial arrhythmias in failing hearts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033810T2 (de) * 1989-10-18 2002-03-28 The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
GB0007268D0 (en) * 2000-03-24 2000-05-17 Cyclacel Ltd Cell cycle progression proteins

Also Published As

Publication number Publication date
EP1436425A2 (de) 2004-07-14
AU2002338852A1 (en) 2003-04-22
DE60234619D1 (de) 2010-01-14
WO2003031650A2 (en) 2003-04-17
EP1436425B1 (de) 2009-12-02
WO2003031650A3 (en) 2004-02-12
GB0124145D0 (en) 2001-11-28

Similar Documents

Publication Publication Date Title
ATE450622T1 (de) Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
EP1900827A3 (de) Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Verhinderung und Behandlung maligner Neoplasien
NO20052348L (no) Behandling av hemoragisk sjokk
WO2005047534A3 (en) Methods and compositions for the response prediction of malig-nant neoplasia to treatment
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO2003013537A3 (en) Irinotecan for treatment of cancer
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
WO2002055024A3 (en) Therapeutic modulation of the tumor inflammatory response
GB0300718D0 (en) Proteins
WO2003027633A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
WO2006037485A3 (en) Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
WO2004111270A3 (en) Differential gene expression in schizophrenia
WO2002097127A3 (en) Genes and proteins for prevention, prediction, diagnosis, prognosis and treatment of chronic lung disease
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
ATE546548T1 (de) Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten
WO2005108605A3 (en) Polymorphisms in abcb1 associated with a lack of clinical response to medicaments
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
ATE374260T1 (de) Asthma-assoziiertes gen
NZ514691A (en) Method to type prion proteins
EP1293570A3 (de) Verwendung des Aprataxin Gens zur Diagnose und Behandlung der früheinsetzenden Hinterstrangataxie (EAOH - early-onset spinocerebellar ataxia)
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties